The SERD Therapeutics Market on a global scale was estimated at USD 1339.0 Mn in 2024 and is projected to attain USD 2108.7 Mn by 2034, with a projected CAGR of 4.8% between 2025 and 2034.
The SERD Therapeutics sector involves a type of drug which downregulates the estrogen receptor. This domain has witnessed considerable transformation owing to technological breakthroughs and shifting healthcare dynamics.
The market's upward path is fueled by growing healthcare spending, technological evolution, and the growing focus on personalized and precision-based approaches in healthcare.
From a segmentation standpoint, the market is categorized across multiple dimensions including product type, application, end-user, and geography, each exhibiting distinct growth patterns and opportunities.
From a regional perspective, mature markets in North America and Europe continue to hold considerable shares, while the Asia-Pacific region is gaining momentum through accelerated economic development and growing investment in the sector.
Competition in this space is characterized by active product development, strategic collaborations, and geographic expansion among both global leaders and specialized niche players.
Through rigorous analysis of market trends, growth catalysts, restraints, and opportunities, this study offers valuable perspectives for companies, investors, and policymakers navigating this evolving landscape.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global SERD Therapeutics Market Snapshot
Chapter 4. Global SERD Therapeutics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Industry Analysis – Porter's Five Forces Analysis
4.6. Competitive Landscape & Market Share Analysis
4.7. Key Trends in the Market
4.8. COVID 19 Impact Analysis
4.9. Clinical Trial/Pipeline Analysis
Chapter 5. Market Segmentation 1: By Products Estimates & Trend Analysis
5.1. By Products & Market Share, 2024 & 2034
5.2. Market Size (Value) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Products:
5.2.1. Faslodex
5.2.2. Elacestrant
5.2.3. Camizestrant (AZD9833)
5.2.4. Giredestrant (GDC-9545)
5.2.5. Imlunestrant (LY3484356)
Other Pipeline Products
Chapter 6. SERD Therapeutics Market Segmentation 2: By Route of Administration Estimates & Trend Analysis
6.1. By Route of Administration Analysis & Market Share, 2024 & 2034
6.2. Market Size (Value) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Route of Administration:
6.2.1. Intramuscular
6.2.2. Oral
6.2.3. Infusion
6.2.4. Subcutaneous
6.2.5. Parenteral
6.2.6. Other
Chapter 6. SERD Therapeutics Market Segmentation 3: By Indication Estimates & Trend Analysis
7.1. By Indication Analysis & Market Share, 2024 & 2034
7.2. Market Size (Value) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Indication:
7.2.1. ER-positive
7.2.2. HER2-negative
7.2.3. ESR1-mutated advanced or metastatic breast cancer.
7.2.4. Other
Chapter 8. SERD Therapeutics Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America SERD Therapeutics Market revenue (US$ Million) estimates and forecasts By Products, 2021-2034
8.1.2. North America SERD Therapeutics Market revenue (US$ Million) estimates and forecasts By Indication, 2021-2034
8.1.3. North America SERD Therapeutics Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2021-2034
8.1.4. North America SERD Therapeutics Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
8.1.4.1. U.S.
8.1.4.2. Canada
8.2. Europe
8.2.1. Europe SERD Therapeutics Market revenue (US$ Million) By Products, 2021-2034
8.2.2. Europe SERD Therapeutics Market revenue (US$ Million) By Indication, 2021-2034
8.2.3. Europe SERD Therapeutics Market revenue (US$ Million) By Route of Administration, 2021-2034
8.2.4. Europe SERD Therapeutics Market revenue (US$ Million) By country, 2021-2034
8.2.4.1. Germany
8.2.4.2. Poland
8.2.4.3. France
8.2.4.4. Italy
8.2.4.5. Spain
8.2.4.6. UK
8.2.4.8. Rest of Europe
8.3. Asia Pacific
8.3.1. Asia Pacific SERD Therapeutics Market revenue (US$ Million) By Products, 2021-2034
8.3.2. Asia Pacific SERD Therapeutics Market revenue (US$ Million) By Indication, 2021-2034
8.3.3. Asia Pacific SERD Therapeutics Market revenue (US$ Million) By Route of Administration, 2021-2034
8.3.4. Asia Pacific SERD Therapeutics Market revenue (US$ Million) By country, 2021-2034
8.3.4.1. China
8.3.4.2. India
8.3.4.3. Japan
8.3.4.4. Australia
8.3.4.5. Rest of Asia Pacific
8.4. Latin America
8.4.1. Latin America SERD Therapeutics Market revenue (US$ Million) By Products, (US$ Million) 2021-2034
8.4.2. Latin America SERD Therapeutics Market revenue (US$ Million) By Indication, (US$ Million) 2021-2034
8.4.3. Latin America SERD Therapeutics Market revenue (US$ Million) By Route of Administration, (US$ Million) 2021-2034
8.4.4. Latin America SERD Therapeutics Market revenue (US$ Million) By country, (US$ Million) 2021-2034
8.4.4.1. Brazil
8.4.4.2. Rest of Latin America
8.5. MEA
8.5.1. MEA revenue SERD Therapeutics Market revenue (US$ Million) By Products, (US$ Million) 2021-2034
8.5.2. MEA revenue SERD Therapeutics Market revenue (US$ Million) By Indication, (US$ Million) 2021-2034
8.5.3. MEA revenue SERD Therapeutics Market revenue (US$ Million) By Route of Administration, (US$ Million) 2021-2034
8.5.4. MEA revenue SERD Therapeutics Market revenue (US$ Million) By country, (US$ Million) 2021-2034
8.5.4.1. South Africa
8.5.4.2. Rest of MEA
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global SERD Therapeutics Market Snapshot
Chapter 4. Global SERD Therapeutics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Industry Analysis – Porter's Five Forces Analysis
4.6. Competitive Landscape & Market Share Analysis
4.7. Key Trends in the Market
4.8. COVID 19 Impact Analysis
4.9. Clinical Trial/Pipeline Analysis
Chapter 5. Market Segmentation 1: By Products Estimates & Trend Analysis
5.1. By Products & Market Share, 2024 & 2034
5.2. Market Size (Value) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Products:
5.2.1. Faslodex
5.2.2. Elacestrant
5.2.3. Camizestrant (AZD9833)
5.2.4. Giredestrant (GDC-9545)
5.2.5. Imlunestrant (LY3484356)
5.2.6. Other Pipeline Products
Chapter 6. SERD Therapeutics Market Segmentation 2: By Route of Administration Estimates & Trend Analysis
6.1. By Route of Administration Analysis & Market Share, 2024 & 2034
6.2. Market Size (Value) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Route of Administration:
6.2.1. Intramuscular
6.2.2. Oral
6.2.3. Infusion
6.2.4. Subcutaneous
6.2.5. Parenteral
6.2.6. Other
Chapter 7. SERD Therapeutics Market Segmentation 3: By Indication Estimates & Trend Analysis
7.1. By Indication Analysis & Market Share, 2024 & 2034
7.2. Market Size (Value) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Indication:
7.2.1. ER-positive
7.2.2. HER2-negative
7.2.3. ESR1-mutated advanced or metastatic breast cancer.
7.2.4. Other
Chapter 8. SERD Therapeutics Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America SERD Therapeutics Market revenue (US$ Million) estimates and forecasts By Products, 2021-2034
8.1.2. North America SERD Therapeutics Market revenue (US$ Million) estimates and forecasts By Indication, 2021-2034
8.1.3. North America SERD Therapeutics Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2021-2034
8.1.4. North America SERD Therapeutics Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
8.1.4.1. U.S.
8.1.4.2. Canada
8.2. Europe
8.2.1. Europe SERD Therapeutics Market revenue (US$ Million) By Products, 2021-2034
8.2.2. Europe SERD Therapeutics Market revenue (US$ Million) By Indication, 2021-2034
8.2.3. Europe SERD Therapeutics Market revenue (US$ Million) By Route of Administration, 2021-2034
8.2.4. Europe SERD Therapeutics Market revenue (US$ Million) By country, 2021-2034
8.2.4.1. Germany
8.2.4.2. Poland
8.2.4.3. France
8.2.4.4. Italy
8.2.4.5. Spain
8.2.4.6. UK
8.2.4.8. Rest of Europe
8.3. Asia Pacific
8.3.1. Asia Pacific SERD Therapeutics Market revenue (US$ Million) By Products, 2021-2034
8.3.2. Asia Pacific SERD Therapeutics Market revenue (US$ Million) By Indication, 2021-2034
8.3.3. Asia Pacific SERD Therapeutics Market revenue (US$ Million) By Route of Administration, 2021-2034
8.3.4. Asia Pacific SERD Therapeutics Market revenue (US$ Million) By country, 2021-2034
8.3.4.1. China
8.3.4.2. India
8.3.4.3. Japan
8.3.4.4. Australia
8.3.4.5. Rest of Asia Pacific
8.4. Latin America
8.4.1. Latin America SERD Therapeutics Market revenue (US$ Million) By Products, (US$ Million) 2021-2034
8.4.2. Latin America SERD Therapeutics Market revenue (US$ Million) By Indication, (US$ Million) 2021-2034
8.4.3. Latin America SERD Therapeutics Market revenue (US$ Million) By Route of Administration, (US$ Million) 2021-2034
8.4.4. Latin America SERD Therapeutics Market revenue (US$ Million) By country, (US$ Million) 2021-2034
8.4.4.1. Brazil
8.4.4.2. Rest of Latin America
8.5. MEA
8.5.1. MEA revenue SERD Therapeutics Market revenue (US$ Million) By Products, (US$ Million) 2021-2034
8.5.2. MEA revenue SERD Therapeutics Market revenue (US$ Million) By Indication, (US$ Million) 2021-2034
8.5.3. MEA revenue SERD Therapeutics Market revenue (US$ Million) By Route of Administration, (US$ Million) 2021-2034
8.5.4. MEA revenue SERD Therapeutics Market revenue (US$ Million) By country, (US$ Million) 2021-2034
8.5.4.1. South Africa
8.5.4.2. Rest of MEA
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Amneal Pharmaceuticals Inc
8.2.2. AstraZeneca, Plc.
8.2.3. Dr. Reddy's Laboratories
8.2.4. Eli Lilly and Company
8.2.5. G1 Therapeutics, Inc.
8.2.6. Glenmark Pharmaceuticals
8.2.7. HBT Labs, Inc
8.2.8. Hoffmann-La Roche AG
8.2.9. InventisBio
8.2.10. Novartis AG
8.2.11. Radius Health
8.2.12. Sanofi S.A.
8.2.13. Teva Pharmaceutical Industries Ltd.
8.2.14. Zenopharm LLC.
8.2.15. Zentalis Pharmaceuticals
8.2.16. Genentech
8.2.17. Olema Pharmaceuticals
8.2.18. Aragon Pharmaceuticals
8.2.19. Sun Pharma Advanced Research Company
8.2.20. Shandong Luoxin Pharmaceutical
8.2.21. Zeno Alpha
8.2.22. Atossa Therapeutics
8.2.23. Evestra